KCT0008619尚未招募未知
Randomized phase II study of maintenance therapy with biologics plus Irinotecan versus biologics plus 5-FU/LV after inductionchemotherapy for metastatic colorectal cancer (ADMIRE)
ational Cancer Center0 个研究点目标入组 138 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Those who voluntarily agreed in writing to participate in the study
- •2. Over 19 years of age
- •3. Histologically or cytologically confirmed metastatic or recurrent colorectal cancer patients
- •4. Bevacizumab or cetuxiamb + FOLFIRI as first-line anticancer therapy for a minimum of 8 cycles and a maximum of 16 cycles
- •Patients who have been treated and have not progressed (if the subject received adjuvant chemotherapy after radical surgery for colorectal cancer,
- •If disease recurs during adjuvant chemotherapy or within 6 months of completing adjuvant chemotherapy, adjuvant chemotherapy is the first line
- •It is considered palliative chemotherapy.)
- •5. If you have a lesion that can be evaluated by RECIST 1.1 (not necessarily a measurable lesion)
- •6. ECOG performance status is 0~2
- •7. Adequate bone marrow function ANC =1,000/µL, platelets =75,000/µL, Hb =8.0g/dL (requires intermittent transfusion
- •You can participate in the study if
- •8. Adequate liver function [total bilirubin =1.5xULN, ALT and ALT =3xULN In case of liver failure: total bilirubin
- •3 x UNL, AST and ALT 5 x UNL)]
- •9. Adequate renal function serum creatinine =1.5xULN or creatinine clearance rate 50 ml/min (Cockroft)]
- •10. A person who understands the contents of the clinical trial, is cooperative with the progress of the trial, and is judged to be able to participate until the end of the study
排除标准
- •1. Cases where R0 or R1 resection of metastatic colorectal cancer was performed before or during first-line chemotherapy (only the primary site
- •Resection or R2 resection is not an exclusion criterion)
- •2. 70% of the recommended dose of either irinotecan or 5 FU at the time of the last round of induction therapy immediately before study enrollment
- •(However, when switching to maintenance therapy, restore the dose of the drug to 70% or more of the recommended dose
- •It is not an exclusion criterion if the researcher judges that it can be started)
- •3. Clinically significant heart disease [unstable angina requiring medication, symptomatic coronary artery disease, New York Heart Association (NYHA) Grade II or higher congestive heart failure or significant cardiac arrhythmia, or acute including myocardial infarction within the past 6 months coronary artery syndrome]
- •4. Active viral infection such as HIV (However, if a prophylactic antiviral agent is used for HBV
- •can be registered)
- •5. Uncontrolled serious infections or other uncontrolled comorbidities
- •6. Symptomatic Inflammatory Bowel Disease
- •7. History of allografts requiring immunosuppressive therapy
- •8. Completely excised basal cell carcinoma of the skin, completely excised cervical carcinoma in situ, treatment including surgery
- •History of other malignancies identified within the past 2 years, excluding thyroid cancer that has been terminated
- •9. Other serious or unstable pre-existing medical or mental problems of the subject during the study
- •If the investigator determines that safety may be threatened
研究者
相似试验
进行中（未招募）
1 期
Clinical trial of combination chemotherapy with anti-angiogenic agent aflibercept in patients with advanced colorectal cancerEUCTR2013-002567-26-GRHellenic Cooperative Oncology Group73
进行中（未招募）
不适用
未命名试验Advanced or metastatic predominantly transitional cell carcinoma of the urothelial tract.MedDRA version: 16.1Level: LLTClassification code 10046722Term: Urothelial carcinoma bladder stage IVSystem Organ Class: 100000004864EUCTR2011-000272-34-DEPIERRE FABRE MEDICAMENT77
进行中（未招募）
不适用
Study to assess the maintenance treatment with Vinflunine after a therapy with gemcitabine and cisplatin in patients with metastatic transitional cell carcinoma of the urothelial tract.EUCTR2011-000272-34-ITPIERRE FABRE MEDICAMENT77
进行中（未招募）
不适用
未命名试验EUCTR2011-000272-34-ATPIERRE FABRE MEDICAMENT77
进行中（未招募）
不适用
Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patientsMETASTATIC BREAST CANCERMedDRA version: 7.0Level: LLTClassification code 10027475EUCTR2004-002759-15-ESDr. Miguel Martín